… tangible potential therapeutic for cerebrovascular diseases. … a tangible potential therapeutic
for cerebrovascular diseases. … use of VEGFA pro-angiogenic therapy can be improved. This …

… cerebrovascular disease during the COVID-19 pandemic, we cannot say with certainty that
the epidemiology of cerebrovascular disease … rate of cerebrovascular events described in this …

… and pathophysiology of the cerebrovascular system [24, 25]. They … as new therapeutic targets
in cerebrovascular diseases and … as a target for the treatment of cerebrovascular diseases. …

… Furthermore, the cerebrovascular degeneration and breakdown of the BBB in AD based on
… Furthermore, new roles of nanodrug delivery to treat AD and other therapeutic drug targets …

… of new therapeutic strategies for this vulnerable age group. With the increasing use of …
therapies, inflammatory pathways and oxidative stress remain attractive therapeutic targets for the …

… therapeutic targets for the treatment of CI and 960 targets for … therapeutic targets for the
treatment of CI and 999 targets for the treatment of MI. Detailed information about those targets is …

… , and therapeutic options. The study of proteomics is particularly enticing for cerebrovascular
diseases … pathways, to understand cerebrovascular pathophysiology, and to develop novel …

… therapy was failing half of our patients led to a change in paradigm of preventive therapy,
“… as blood pressure and LDL-C to consensus targets. The goal is to stop plaque progression …

… Overall, the importance of PVMs has been increasingly recognized and highlighted, with
PVMs explored as a significant pathophysiological element and a novel therapeutic target in …

… In summary, an attractive therapeutic strategy for mixed cerebrovascular disease is one that
utilizes agents acting on both platelets and vessel wall. Several PDE inhibitors have those …